Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028

December 2023 | 1500 pages | ID: GA0CC3DFF48AEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028 Report Findings & Highlights:

• Global Cancer Antibody Combinations Market Opportunity: > USD 40 Billion By 2028
• Insight On Approved Cancer Antibody Combinations In Market: > 65 Antibodies Combinations
• Insight On Cancer Antibody Combinations In Clinical Trials: > 450 Antibodies Combinations
• Patent, Pricing, & Dosage Insight On Approved Combinations
• Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication & Phase
• Global Antibody Combinations Market Development by Region & Indications

Combinations Included In Report:

• Approved Antibody - Antibody Combinations
• Approved Antibody - Small Molecule Inhibitors Combinations
• Approved Antibody - Immunomodulatory Agents Combinations
• Approved Antibody - Chemotherapy Combinations
• Approved Antibody - Mixed Combinations
• Ongoing Clinical Trials Combination With Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Radiotherapy

In recent years, the landscape of cancer therapeutics has witnessed a paradigm shift with the emergence of antibody combination therapies, a dynamic approach that intertwines the precision of antibodies to target specific molecules with the synergistic benefits of different types of antibodies. By merging different types of monoclonal antibodies with other therapeutic agents, numerous pathways that are involved in the pathogenesis of cancer may be targeted simultaneously, thereby, possibly leading to additive or else synergistic effects. Theoretically, the combinations of antibodies are very suitable approach that can be employed for the treatment of cancer modalities because of the fact that the antibody combination therapy aids to limit overlapping toxicity along with lack of pharmacokinetic (PK) interactions.

The hypothesis of combining antibodies with other therapeutic agents began in the late 1990s when the researchers together with scientists amplified the preclinical testing that includes a combinations of monoclonal antibodies (mAb) with chemotherapy, radiotherapy or any other therapeutic agents in order to address the occurrence of drug resistant strains or the escape mechanism for observed in cancer malignancies. The main purpose of these investigations was to expand the therapeutic index as well as the potential of mAbs. Advantages such as amended efficiency, diminished toxicities, delayed development of therapy or drug resistances in addition dose reduction were observed in the preclinical studies that come along with antibody combinations.

In dichotomy with the conventional treatments such as chemotherapy and radiotherapy, which clenches the possibility to damage healthy cells, with the arrival of antibody combination therapies has transformed the landscape of targeted medicine. As of now, multiple antibody combination therapies such as Phesgo, Herceptin with Perjeta, Ramucirumab with docetaxel, atezolizumab, Bevacizumab with chemotherapy, atezolizumab and bevacizumab, and ipilimumab and nivolumab etc have been approved by the FDA, EMA, NICE and others for the treatment of diverse type of cancers.

In the realm of cancer therapy, the preliminary clinical development for the domain of antibody combinations were focused on creating anti-PD-1, anti-CTLA-4 and anti-PD-L1 monoclonal antibody (mAb) combinations, there has been modern improvement observed in harnessing the potential of mAb in conjugation with chemotherapy or with various oral small molecule multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) or platelet derived growth factor receptor (PDGFR) as the first-line treatment for multiple types of cancer like advanced solid tumors, hematological cancer, etc. Zhejiang University based in China is conducting clinical studies in which the combination of anti-PD-1 antibody with Donafenib, multikinase inhibitor, is ongoing to evaluate the safety and efficacy of the treatment regimen.

Another pharmaceutical company based in China, Chia Tai Tianqing Pharmaceutical Group reported another combination of anti-PD-1 antibody, Penpulimab with multi targeted receptor TKI, Anlotinib for the treatment of patients suffering from hepatocellular cancer (HCC). The primary goal of this study is to assess the effectiveness of combined treatment regimen for adjuvant therapy. It is a randomized, double-blind, placebo-controlled, multicenter phase 3 study which was initiated in May 2023 and is expected to be complete by December 2026.

Hitherto, the clinical pipeline for the domain of antibody combination therapy for treating cancer modalities majorly consists of immune checkpoint inhibitors, such as CTLA-4, PD-1 and PD-L1, PP2A inhibitors, CDK4/6 inhibitors, mAbs targeting HER 2, TIGIT mAbs, bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. It is expected that the imminent years will certainly witness innovative antibody combinations for the treatment of cancer malignancies as evident from augmenting interest in pharmaceutical sectors and fostering FDA designations to novel combination therapy. For instance, in August 2023, Agenus was granted the Fast Track Designation for its innovative antibody combination, botensilimab (AGEN1181) and balstilimab (AGEN2034) for the treatment of colorectal cancer patients.

With the increasing prevalence of cancer types at an alarming gait urges the need to develop better as well as innovative antibody combination therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe. Furthermore, an inclining market trend towards utilizing the realm of antibody combination has been observed due to involvement of various stakeholders from pharmaceutical and biotech companies such as Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Agenus, Novartis, Celldex Therapeutics and Merck. With the current market scenario, the future of the antibody combination market looks promising and is expected to multiple further as evident from the growing clinical trials, rising research and development and involvement of various stakeholders in the domain.

Contents

1. INTRODUCTION TO CANCER ANTIBODY COMBINATIONS

1.1 History, Development & Evolution
1.2 Approved Cancer Antibody Combinations

2. NEED OF ANTIBODY COMBINATIONS


3. GLOBAL CANCER ANTIBODY COMBINATIONS MARKET & CLINICAL DEVELOPMENT INSIGHT

3.1 Current Market Scenario
3.2 Future Outlook

4. GLOBAL ANTIBODY COMBINATIONS MARKET INSIGHT BY REGION

4.1 US
4.2 China
4.3 Europe
4.4 Japan
4.5 UK
4.6 Canada
4.7 South Korea

5. GLOBAL CANCER ANTIBODY COMBINATIONS CLINICAL TRIALS OVERVIEW

5.1 By Antibody Classification
5.2 By Breakthrough Therapy & Fast Track Status
5.3 By Company
5.4 By Country
5.5 By Indication
5.6 By Phase

6. GLOBAL ANTIBODY COMBINATIONS MARKET INSIGHT BY INDICATION

6.1 Lung Cancer
6.2 Melanoma
6.3 Breast Cancer
6.4 Hepatocellular Cancer
6.5 Colorectal Cancer
6.6 Renal Cell Carcinoma
6.7 Lymphoma
6.8 Leukemia
6.9 Multiple Myeloma

7. GLOBAL CANCER ANTIBODY COMBINATIONS CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered

8. APPROVED/MARKETED CANCER ANTIBODY COMBINATIONS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY & INDICATION


9. ANTIBODY - ANTIBODY COMBINATIONS – PRICING, PATENT & DOSING INSIGHT

9.1 Opdivo + Yervoy
  9.1.1 Overview & Patent Insight
  9.1.2 Pricing & Dosage Insight
9.2 Opdualag (nivolumab & relatlimab)
  9.2.1 Overview & Patent Insight
  9.2.2 Pricing & Dosage Insight
9.3 Imjudo + Imfinzi
  9.3.1 Overview & Patent Insight
  9.3.2 Pricing & Dosage Insight
Detailed Combinations Are Mentioned in Report Sample

10. ANTIBODY - SMALL MOLECULE INHIBITORS COMBINATIONS – PRICING, PATENT & DOSING INSIGHT

10.1 Gazyva + Imbruvica
  10.1.1 Overview & Patent Insight
  10.1.2 Pricing & Dosage Insight
10.2 Imbruvica + Rituximab
  10.2.1 Overview & Patent Insight
  10.2.2 Pricing & Dosage Insight
10.3 Bavencio + Inlyta
  10.3.1 Overview & Patent Insight
  10.3.2 Pricing & Dosage Insight
Detailed Combinations Are Mentioned in Report Sample

11. ANTIBODY - IMMUNOMODULATORY AGENTS COMBINATIONS – PRICING, PATENT & DOSING INSIGHT

11.1 Monjuvi + lenalidomide
  11.1.1 Overview & Patent Insight
  11.1.2 Pricing & Dosage Insight
11.2 Avastin + Interferon-alfa
  11.2.1 Overview & Patent Insight
  11.2.2 Pricing & Dosage Insight

12. ANTIBODY - CHEMOTHERAPY COMBINATIONS – PRICING, PATENT & DOSING INSIGHT

12.1 Jemperli
  12.1.1 Overview & Patent Insight
  12.1.2 Pricing & Dosage Insight
12.2 Cyramza
  12.2.1 Overview & Patent Insight
  12.2.2 Pricing & Dosage Insight
12.3 Portrazza
  12.3.1 Overview & Patent Insight
  12.3.2 Pricing & Dosage Insight
Detailed Combinations Are Mentioned in Report Sample

13. ANTIBODY - MIXED COMBINATIONS

13.1 Phesgo (Perjeta + Herceptin + hyaluronidase)
  13.1.1 Overview & Patent Insight
  13.1.2 Pricing & Dosage Insight
13.2 Darzalex
  13.2.1 Overview & Patent Insight
  13.2.2 Pricing & Dosage Insight
13.3 Empliciti
  13.3.1 Overview & Patent Insight
  13.3.2 Pricing & Dosage Insight
Detailed Combinations Are Mentioned in Report Sample

14. COMPETITIVE LANDSCAPE

14.1 AbbVie
14.2 Adagene
14.3 Agenus
14.4 Akeso Biopharma
14.5 Amgen
14.6 AstraZeneca
14.7 BeiGene
14.8 Biocad
14.9 BioInvent International
14.10 Bio-Thera Solutions
14.11 Boehringer Ingelheim
14.12 Bristol-Myers Squibb
14.13 Concentra Biosciences
14.14 Daiichi Sankyo Company
14.15 Eli Lilly and Company
14.16 Eucure Biopharma
14.17 Genentech
14.18 Genmab
14.19 GSK
14.20 ImmunoGen
14.21 Innovent Biologics
14.22 Janssen Research & Development
14.23 Jiangsu Hengrui Medicine Co.
14.24 LaNova Medicines Limited
14.25 Lepu Biopharma
14.26 MacroGenics
14.27 Merck
14.28 Merus
14.29 NGM Biopharmaceuticals
14.30 Novartis
14.31 Pfizer
14.32 Regeneron Pharmaceuticals
14.33 Roche
14.34 Seagen
14.35 Shanghai Henlius Biotech
14.36 Shanghai Junshi Biosciences
14.37 Sinocelltech
14.38 Symphogen
14.39 UCB
14.40 Xencor

List Of Figures

LIST OF FIGURES

Figure 1-1: Developmental Milestones for Antibody Combinations
Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination
Therapy
Figure 2-2: Need of Antibody Combinations
Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents
Figure 2-4: Expected Antibody Combinations
Figure 3-1: Global – Cancer Antibody Combination Market Opportunity (US$ Billion),

2023 - 2028

Figure 3-2: Antibody Combination Market - Prominent Regions
Figure 3-3: Aspects of Current Antibody Combinations Market
Figure 3-4: Future Characteristics of Antibody Combinations Market
Figure 4-1: COMBI-i Phase III Study – Initiation & Completion Years
Figure 4-2: CONTACT-01 Phase III Study – Initiation & Completion Years
Figure 4-3: NCT05800015 Phase II//III Study – Initiation & Completion Years
Figure 4-4: MagnetisMM-4 Phase II Study – Initiation & Completion Years
Figure 4-5: DREAMM 6 Phase I/II Study – Initiation & Completion Years
Figure 4-6: NCT04421352 Phase I Study – Initiation & Completion Year
Figure 4-7: NCT05867121 Phase I Study – Initiation & Completion Year
Figure 4-8: NCT06054477 Phase I/II Study – Initiation & Completion Year
Figure 4-9: NCT04868877 Phase I/II Study – Initiation & Completion Year
Figure 4-10: NCT05867121 Phase I Study – Initiation & Completion Year
Figure 4-11: NCT06038578 Phase II Study – Initiation & Completion Year
Figure 4-12: DESTINY-Breast01 Phase II Study – Initiation & Completion Year
Figure 4-13: BI-1607 & Trastuzumab Phase I/II Study – Initiation & Completion Year
Figure 4-14: Myechild01 Phase III Study – Initiation & Completion Year
Figure 4-15: GS-9911 & Zimberelimab Phase I Study – Initiation & Completion Year
Figure 4-16: EGIA-002 Phase II Study – Initiation & Completion Year
Figure 4-17: TUC1PI-01 Phase I/II Study – Initiation & Completion Year
Figure 4-18: TUC1PI-01 Phase I/II Study – Initiation & Completion Year
Figure 4-19: LEAP-008 Phase III Study – Initiation & Completion Year
Figure 4-20: VOLGA Phase III Study – Initiation & Completion Year
Figure 4-21: MarkV-01 Phase I Study – Initiation & Completion Year
Figure 5-1: Global – Cancer Antibody Combinations Clinical Trials By Antibody
Classification, 2023 till 2028
Figure 5-2: Global – Cancer Antibody Combinations Clinical Trials By Priority Status,

2023 TILL 2028

Figure 5-3: Global – Cancer Antibody Combinations Clinical Trials By Company, 2023
till 2028
Figure 5-4: Global – Cancer Antibody Combinations Clinical Trials By Country, 2023
till 2028
Figure 5-5: Global – Cancer Antibody Combinations Clinical Trials By Indication, 2023
till 2028
Figure 5-6: Global – Cancer Antibody Combinations Clinical Trials By Phase, 2023 till

2028

Figure 6-1: Lung Cancer – Approved Antibody Combinations
Figure 6-2: Cemiplimab & Fianlimab Phase II/III Study – Initiation & Completion Year
Figure 6-3: Daratumumab, Nivolumab & KRAS vaccine Phase II Study – Initiation &
Completion Year
Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations
Figure 6-5: Melanoma – Approved Antibody Combinations
Figure 6-6: NCT05608291 Phase III Study – Initiation & Completion Year
Figure 6-7: OrienX010-II-11 Phase I Study – Initiation & Completion Year
Figure 6-8: MM1636 Phase I/II Study – Initiation & Completion Year
Figure 6-9: Breast Cancer - Approved Antibody Combinations
Figure 6-10: Trastuzumab & Pyrotinib Phase III Study – Initiation & Completion Year
Figure 6-11: Inetetamab, Toripalimab & Paclitaxel Phase IV Study – Initiation &
Completion Year
Figure 6-12: Breast Cancer – Key Player in Antibody Combination Commercial Market
Figure 6-13: Breast Cancer – Different Antibody Combination With Other
Therapeutic Agents
Figure 6-14: Hepatocellular Cancer– Approved Antibody Combinations
Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular
Carcinoma
Figure 6-16: Penpulimab & Anlotinib Phase III Study – Initiation & Completion Year
Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company
Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer
Figure 6-19: NCT06099951 Phase II Study – Initiation & Completion Year
Figure 6-20: KEYFORM-007 Phase III Study – Initiation & Completion Year
Figure 6-21: Renal Cell Carcinoma – Approved Antibody Combinations
Figure 6-22: SillaJen & Regeneron Pharmaceuticals – Novel Approach of Combining
Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma
Figure 6-23: BMC128 & Nivolumab Phase I Study – Initiation & Completion Year
Figure 6-24: Lymphoma – Approved Antibody Combinations
Figure 6-25: NCT04464798 Phase I Study – Initiation & Completion Year
Figure 6-26: Odronextamab, Lenalidomide & Rituximab Phase III Study – Initiation &
Completion Year
Figure 6-27: L-DEP & PD-1 Antibody Phase III Study – Initiation & Completion Year
Figure 6-28: Collaboration of MorphoSys & Incyte, IGM Bioscience & ADC
Therapeutic, 2022
Figure 6-29: Leukemia – Approved Antibody Combinations
Figure 6-30: NCT06043674 Phase II Study – Initiation & Completion Year
Figure 6-31: NP137, Venetoclax & Azacitidine Phase I/II Study – Initiation &
Completion Year
Figure 6-32: Novartis – Hypothesis for Phase 3 Clinical Study
Figure 6-33: Sabatolimab & Azacitidine Phase III Study – Initiation & Completion
Year
Figure 6-34: Multiple Myeloma – Approved Antibody Combinations
Figure 6-35: NCT05730036 Phase III Study – Initiation & Completion Year
Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple
Myeloma
Figure 6-37: NCT05363111 Phase I Study – Initiation & Completion Year
Figure 9-1: Opdivo & Yervoy – Minimum Market Exclusivity Year by Region
Figure 9-2: Opdivo & Yervoy – FDA Approval Years by Indications
Figure 9-3: Opdivo & Yervoy – EMA Approval Years by Indications
Figure 9-4: US – Opdivo Cost per Unit & Supply (US$), December’2023
Figure 9-5: US – Yervoy Cost per Unit & Supply (US$), December’2023
Figure 9-6: EU – Opdivo Cost of Supply (US$), November’2023
Figure 9-7: EU – Yervoy Cost of Supply (US$), November’2023
Figure 9-8: Opdualag – Approval Years by Region
Figure 9-9: Opdualag – Minimum Market Exclusivity Year by Region
Figure 9-10: US & EU – Opdualag Cost per Supply (US$), November’2023
Figure 9-11: Imfinzi & Imjudo – Patent Expiry Years by Region
Figure 9-12: US – Imfinzi Cost per Unit & Supply (US$), November’2023
Figure 9-13: US – Imjudo Cost per Unit & Supply (US$), November’2023
Figure 9-14: EU – Imfinzi Cost per Unit & Supply (US$), November’2023
Figure 9-15: EU – Imjudo Cost per Unit & Supply (US$), November’2023
Figure 9-16: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-17: US – Padcev Cost per Unit & Supply (US$), November’2023
Figure 9-18: EU – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-19: EU – Padcev Cost per Unit & Supply (US$), November’2023
Figure 9-20: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-21: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 9-22: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 9-23: EU – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-24: US – Tecentriq Cost per Unit & Supply (US$), November’2023
Figure 9-25: US – Avastin Cost per Unit & Supply (US$), November’2023
Figure 9-26: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
November’2023
Figure 9-27: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
November’2023
Figure 9-28: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml &

160ML (US$), NOVEMBER’2023

Figure 9-29: EU – Tecentriq Cost per Unit & Supply (US$), November’2023
Figure 9-30: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
November’2023
Figure 9-31: US – Perjeta Cost per Unit & Supply (US$), November’2023
Figure 9-32: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 9-33: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 9-34: EU – Perjeta Cost per Supply (US$), November’2023
Figure 9-35: US – Polivy Cost per Supply (US$), November’2023
Figure 9-36: US – Rituxan Cost per Unit & Supply (US$), November’2023
Figure 9-37: US – Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$),
November’2023
Figure 9-38: US – Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$),
November’2023
Figure 9-39: EU – Polivy Cost per Supply (US$), November’2023
Figure 9-40: EU – Rituximab Biosimilar Truxima Cost per Supply (US$),
November’2023
Figure 10-1: US – Imbruvica Cost per Unit & Supply of 70mg (US$), November’2023
Figure 10-2: US – Imbruvica Cost per Unit & Supply of 140mg (US$), November’2023
Figure 10-3: US – Gazyva Cost per Unit & Supply (US$), November’2023
Figure 10-4: US – Imbruvica Cost per Unit & Supply of 70mg (US$), November’2023
Figure 10-5: US – Imbruvica Cost per Unit & Supply of 140mg (US$), November’2023
Figure 10-6: US – Rituxan Cost per Unit & Supply (US$), November’2023
Figure 10-7: US – Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$),
November’2023
Figure 10-8: US – Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$),
November’2023
Figure 10-9: EU – Rituximab Biosimilar Truxima Cost per Supply (US$),
November’2023
Figure 10-10: US – Bavencio Cost per Unit & Supply (US$), November’2023
Figure 10-11: US – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-12: EU – Bavencio Cost per Unit & Supply (US$), November’2023
Figure 10-13: EU – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-14: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 10-15: US – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-16: EU – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 10-17: EU – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-18: US – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 10-19: US – Tarceva Cost per Supply (US$), December’2023
Figure 10-20: EU – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 10-21: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 10-22: US – Lenvima Cost per Unit & Supply (US$), November’2023
Figure 10-23: EU – Keytruda Cost per Unit & Supply (US$), December’2023
Figure 10-24: US – Opdivo Cost per Unit & Supply (US$), November’2023
Figure 10-25: US – Cabometyx Cost per Unit & Supply (US$), November’2023
Figure 10-26: EU – Opdivo Cost per Unit & Supply (US$), November’2023
Figure 10-27: EU – Cabometyx Cost per Unit & Supply (US$), November’2023
Figure 11-1: US – Monjuvi Cost of Supply (US$), December’2023
Figure 11-2: US – Revlimid Cost per Unit & Supply (US$), December’2023
Figure 11-3: US – Avastin Cost per Unit & Supply (US$), December’2023
Figure 11-4: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
December’2023
Figure 11-5: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
December’2023
Figure 11-6: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml &

160ML (US$), DECEMBER’2023

Figure 11-7: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
December’2023
Figure 12-1: US & EU – Jemperli Cost of Supply (US$), December’2023
Figure 12-2: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-3: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-4: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-5: US – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 12-6: EU – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 12-7: US – Taxotere Cost per Unit & Supply (US$), December’2023
Figure 12-8: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-9: US & EU – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 12-10: US – Gemzar Cost of Supply (US$), December’2023
Figure 12-11: US – Infugem Cost per Unit & Supply (US$), December’2023
Figure 12-12: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-13: US – Vectibix Cost per Unit & Supply (US$), December’2023
Figure 12-14: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 12-15: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 12-16: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-17: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-18: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-19: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-20: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December’2023
Figure 12-21: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-22: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-23: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$),
December’2023
Figure 12-24: US – Adriamycin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-25: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-26: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-27: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-28: US – Vincristine Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-29: US – Toposar Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-30: US – Etoposide Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-31: US – Etoposide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-32: US – Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$),
December’2023
Figure 12-33: US – Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$),
December’2023
Figure 12-34: US – Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$),
December’2023
Figure 12-35: US – Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$),
December’2023
Figure 12-36: US – Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$),
December’2023
Figure 12-37: US – Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$),
December’2023
Figure 12-38: US – Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$),
December’2023
Figure 12-39: US – Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$),
December’2023
Figure 12-40: US – Vinblastine Cost per Unit & Supply (US$), December’2023
Figure 12-41: US – Dacarbazine Cost per Unit & Supply for 100mg Intravenous
Powder (US$), December’2023
Figure 12-42: US – Dacarbazine Cost per Unit & Supply for 200mg Intravenous
Powder (US$), December’2023
Figure 12-43: US – Erbitux Cost per Unit & Supply (US$), December’2023
Figure 12-44: US – Camptosar Cost per Unit & Supply (US$), December’2023
Figure 12-45: US – Irinotecan Cost per Unit & Supply (US$), December’2023
Figure 12-46: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-47: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-48: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-49: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-50: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-51: US – Leucovorin Cost of Supply of 100mg, 200mg, 350mg & 500mg
Injectable Powder (US$), December’2023
Figure 12-52: US – Leucovorin Cost per Unit & Supply of Injectable Solution (US$),
December’2023
Figure 12-53: US - Leucovorin Cost per Unit & Supply of 5mg Oral Tablet (US$),
December’2023
Figure 12-54: US - Leucovorin Cost per Unit & Supply of 10mg Oral Tablet (US$),
December’2023
Figure 12-55: US - Leucovorin Cost per Unit & Supply of 15mg Oral Tablet (US$),
December’2023
Figure 12-56: US - Leucovorin Cost per Unit & Supply of 25mg Oral Tablet (US$),
December’2023
Figure 12-57: US – Avastin Cost per Unit & Supply (US$), December’2023
Figure 12-58: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
December’2023
Figure 12-59: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
December’2023
Figure 12-60: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml
& 160ml (US$), December’2023
Figure 12-61: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
December’2023
Figure 12-62: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-63: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-64: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-65: US – Tecentriq Cost per Unit & Supply (US$), November’2023
Figure 12-66: US – Gemzar Cost of Supply (US$), December’2023
Figure 12-67: US – Infugem Cost per Unit & Supply (US$), December’2023
Figure 12-68: US – Hycamtin Cost of Supply of Oral Capsule (US$), December’2023
Figure 12-69: US – Topotecan Cost of Supply of Intravenous Solution (US$),
December’2023
Figure 12-70: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 12-71: EU – Keytruda Cost of Supply (US$), November’2023
Figure 12-72: US – Xeloda Cost per Unit & Supply (US$), November’2023
Figure 12-73: US – Capecitabine Cost per Unit & Supply of 150mg (US$),
November’2023
Figure 12-74: US – Capecitabine Cost per Unit & Supply of 500mg (US$),
November’2023
Figure 12-75: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-76: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-77: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-78: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December’2023
Figure 12-79: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-80: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-81: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$),
December’2023
Figure 12-82: US – Adriamycin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-83: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-84: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-85: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-86: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-87: US – Abraxane Cost per Unit & Supply (US$), December’2023
Figure 12-88: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-89: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-90: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-91: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 12-92: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 12-93: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-94: US – Gemzar Cost of Supply (US$), December’2023
Figure 12-95: US – Infugem Cost per Unit & Supply (US$), December’2023
Figure 12-96: US – Gemcitabine Cost of Supply of Intravenous Powder for Injection
(US$), December’2023
Figure 12-97: US – Gemcitabine Cost per Unit & Supply of 38mg/ml Intravenous
Solution (US$), December’2023
Figure 12-98: US – Gemcitabine Cost per Unit & Supply of 100mg/ml Intravenous
Solution (US$), December’2023
Figure 12-99: US – Alimta Cost of Supply (US$), December’2023
Figure 12-100: US – Pemfexy Cost per Unit & Supply (US$), December’2023
Figure 12-101: US – Pemetrexed Cost per Unit & Supply of Intravenous Powder for
Injection (US$), December’2023
Figure 12-102: US – Pemetrexed Cost per Unit & Supply of Intravenous Solution
(US$), December’2023
Figure 12-103: US – Ellence Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-104: US – Epirubicin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-105: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 12-106: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 12-107: US – Xeloda Cost per Unit & Supply (US$), November’2023
Figure 12-108: US – Capecitabine Cost per Unit & Supply of 150mg (US$),
November’2023
Figure 12-109: US – Capecitabine Cost per Unit & Supply of 500mg (US$),
November’2023
Figure 12-110: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-111: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-112: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-113: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Doses 1g/2ml, 2g/4ml & 500mg/ml (US$), December’2023
Figure 12-114: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-115: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-116: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$),
December’2023
Figure 12-117: US – Adriamycin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-118: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-119: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-120: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution
(US$), December’2023
Figure 12-121: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-122: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-123: US – Libtayo Cost per Unit & Supply (US$), December’2023
Figure 12-124: US – Libtayo Cost per Unit & Supply (US$), December’2023
Figure 12-125: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-126: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-127: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-128: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 12-129: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 12-130: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 13-1: US – Phesgo Cost per Unit & Supply (US$), December’2023
Figure 13-2: EU – Phesgo Cost per Unit & Supply (US$), December’2023
Figure 13-3: US - Darzalex Cost per Unit & Supply (US$), November’2023
Figure 13-4: EU - Darzalex Cost per Unit & Supply (US$), December’2023
Figure 13-5: US – Kyprolis Cost per Unit & Supply (US$), November’2023
Figure 13-6: US – Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable
Solution (US$), December’2023
Figure 13-7: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable
Solution (US$), December’2023
Figure 13-8: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December’2023
Figure 13-9: US – Dexamethasone Cost per Unit & Supply of Oral Liquid (US$),
December’2023
Figure 13-10: US – Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg
& 6mg Oral Tablets (US$), December’2023
Figure 13-11: US – Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets
(US$), December’2023
Figure 13-12: US – Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets
(US$), December’2023
Figure 13-13: US – Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets
(US$), December’2023
Figure 13-14: US – Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets
(US$), December’2023
Figure 13-15: US – TaperDex Cost per Unit & Supply (US$), December’2023
Figure 13-16: US – Velcade Cost per Supply (US$), November’2023
Figure 13-17: US – Bortezomib Cost of Supply (US$), December’2023
Figure 13-18: US – Thalomid Cost per Unit & Supply of 50mg Capsule (US$),
December’2023
Figure 13-19: US – Thalomid Cost per Unit & Supply of 100mg & 150mg Capsules
(US$), December’2023
Figure 13-20: US – Revlimid Cost per Unit & Supply (US$), December’2023
Figure 13-21: US – Pomalyst Cost per Unit & Supply (US$), December’2023
Figure 13-22: US – Evomela & Generic Melphalan Cost of Supply (US$),
December’2023
Figure 13-23: US – Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$),
December’2023
Figure 13-24: US – Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$),
December’2023
Figure 13-25: US – Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$),
December’2023
Figure 13-26: US – Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$),
December’2023
Figure 13-27: US – Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$),
December’2023
Figure 13-28: US – Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$),
December’2023
Figure 13-29: US – Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$),
December’2023
Figure 13-30: US – Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$),
December’2023
Figure 13-31: US - Empliciti Cost of Supply (US$), November’2023
Figure 13-32: US – Pomalyst Cost per Unit & Supply (US$), December’2023
Figure 13-33: US – Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable
Solution (US$), December’2023
Figure 13-34: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable
Solution (US$), December’2023
Figure 13-35: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December’2023
Figure 13-36: US – Dexamethasone Cost per Unit & Supply of Oral Liquid (US$),
December’2023
Figure 13-37: US – Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg,

1MG, & 6MG ORAL TABLETS (US$), DECEMBER’2023

Figure 13-38: US – Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets
(US$), December’2023
Figure 13-39: US – Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets
(US$), December’2023
Figure 13-40: US – Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets
(US$), December’2023
Figure 13-41: US – Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets
(US$), December’2023
Figure 13-42: US – TaperDex Cost per Unit & Supply (US$), December’2023
Figure 13-43: US – Keytruda Cost per Unit & Supply (US$), December’2023
Figure 13-44: EU – Keytruda Cost of Supply (US$), December’2023
Figure 13-45: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 13-46: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 13-47: US – Avastin Cost per Unit & Supply (US$), December’2023
Figure 13-48: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
December’2023
Figure 13-49: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
December’2023
Figure 13-50: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml
& 160ml (US$), December’2023
Figure 13-51: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
December’2023
Figure 13-52: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 13-53: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 13-54: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 13-55: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 13-56: US – Xeloda Cost per Unit & Supply (US$), November’2023
Figure 13-57: US – Capecitabine Cost per Unit & Supply of 150mg (US$),
November’2023
Figure 13-58: US – Capecitabine Cost per Unit & Supply of 500mg (US$),
November’2023
Figure 13-59: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 13-60: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 13-61: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 13-62: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 13-63: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 13-64: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 13-65: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 13-66: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 13-67: US – Sarclisa Cost per Unit & Supply (US$), December’2023
Figure 13-68: US – Kyprolis Cost per Unit & Supply (US$), December’2023
Figure 13-69: EU – Sarclisa Cost per Unit & Supply (US$), December’2023
Figure 13-70: US – Pomalyst Cost per Unit & Supply (US$), December’2023

List Of Tables

LIST OF TABLES

Table 1-1: Global – Approved Cancer Antibody Combinations
Table 9-1: Opdivo & Yervoy Combination – Recommended Dosages
Table 9-2: Imjudo & Imfinzi - Recommended Dosage Schedule for Treatment of
NSCLC
Table 10-1: Dose of Gazyva to be Administered During Six 28-Day Treatment Cycles
for Patients with CLL
Table 10-2: Cabometyx & Nivolumab - Recommended Dosage of Combination
Table 11-1: Monjuvi - Dosing Schedule
Table 12-1: Jemperli - Recommended Dosage
Table 12-2: US – Approved Cyramza-Chemotherapy Combinations
Table 12-3: US – Approved Vectibix-Chemotherapy Combinations
Table 12-4: US – Approved Adcetris-Chemotherapy Combinations
Table 12-5: Adcetris - Recommended Dosage
Table 12-6: US – Approved Erbitux-Chemotherapy Combinations
Table 12-7: US – Approved Avastin-Chemotherapy Combinations
Table 12-8: US – Approved Keytruda-Chemotherapy Combinations
Table 12-9: Keytruda - Recommended Doses
Table 12-10: US – Approved Herceptin-Chemotherapy Combinations
Table 13-1: Phesgo: Recommended Dosage & Administration Schedule
Table 13-2: US – Approved Darzalex-Chemotherapy Combinations
Table 13-3: Darzalex - Dosing Schedule in Combination with Lenalidomide or
Pomalidomide (4-Week Cycle) & Low-Dose Dexamethasone
Table 13-4: Darzalex - Dosing Schedule in Combination with Bortezomib, &
Prednisone ([VMP], 6-Week Cycle)
Table 13-5: Darzalex - Dosing Schedule in Combination with Bortezomib,
Thalidomide & Dexamethasone ([VTd]; 4-Week Cycle)
Table 13-6: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week
Cycle)
Table 13-7: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week
Cycle)
Table 13-8: Empliciti - Recommended Dosing Schedule in Combination with
Lenalidomide & Dexamethasone
Table 13-9: Empliciti - Recommended Dosing Schedule in Combination with
Pomalidomide & Dexamethasone
Table 13-10: US – Approved Keytruda-Chemotherapy Combinations
Table 13-11: Keytruda - Recommended Dosage
Table 13-12: US – Approved Sarclisa-Chemotherapy Combinations
Table 13-13: Sarclisa - Dosing Schedule in Combination with Pomalidomide &
Dexamethasone or in Combination with Carfilzomib & Dexamethasone